Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Alexandar Tchaouchev was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 10
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Sep 19
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Jun 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • May 26
Sopharma AD, Annual General Meeting, Jun 27, 2025 Sopharma AD, Annual General Meeting, Jun 27, 2025, at 11:00 FLE Standard Time. Location: sofia at 5 lachezar stanchev st, sofia Bulgaria Board Change • Apr 28
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Dec 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Nov 01
Upcoming dividend of лв0.075 per share Eligible shareholders must have bought the stock before 07 November 2024. Payment date: 23 December 2024. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 17%. Within top quartile of Bulgarian dividend payers (5.0%). Higher than average of industry peers (2.4%). Reported Earnings • Sep 01
Second quarter 2024 earnings released: EPS: лв0.081 (vs лв0.26 in 2Q 2023) Second quarter 2024 results: EPS: лв0.081 (down from лв0.26 in 2Q 2023). Revenue: лв495.1m (up 9.3% from 2Q 2023). Net income: лв16.1m (down 48% from 2Q 2023). Profit margin: 3.3% (down from 6.9% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Jun 26
Independent Director recently bought лв331k worth of stock On the 24th of June, Alexandar Tchaoushev bought around 56k shares on-market at roughly лв5.96 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold лв958k more in shares than they bought in the last 12 months. Recent Insider Transactions • Jun 13
Chairman recently bought лв124k worth of stock On the 10th of June, Ognian Donev bought around 20k shares on-market at roughly лв6.20 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.4m. Reported Earnings • Jun 04
First quarter 2024 earnings released: EPS: лв0.23 (vs лв0.27 in 1Q 2023) First quarter 2024 results: EPS: лв0.23 (down from лв0.27 in 1Q 2023). Revenue: лв514.0m (up 9.5% from 1Q 2023). Net income: лв29.7m (down 7.9% from 1Q 2023). Profit margin: 5.8% (down from 6.9% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 20% per year. Buy Or Sell Opportunity • Mar 06
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 9.2% to лв6.66. The fair value is estimated to be лв5.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.1% over the last 3 years. Earnings per share has grown by 25%. Revenue is forecast to grow by 5.3% in a year. Earnings are forecast to decline by 24% in the next year. Reported Earnings • Mar 03
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: лв0.73 (up from лв0.58 in FY 2022). Revenue: лв1.90b (up 13% from FY 2022). Net income: лв95.2m (up 34% from FY 2022). Profit margin: 5.0% (up from 4.3% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Over the last 3 years on average, earnings per share has increased by 25% per year whereas the company’s share price has increased by 24% per year. New Risk • Jan 25
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 12% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (0.9% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 225% Paying a dividend despite having no free cash flows. Earnings are forecast to decline by an average of 12% per year for the foreseeable future. Minor Risks Profit margins are more than 30% lower than last year (4.4% net profit margin). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв791k sold). Recent Insider Transactions • Dec 21
Chairman recently sold лв527k worth of stock On the 12th of December, Ognian Donev sold around 86k shares on-market at roughly лв6.10 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.7m. Recent Insider Transactions • Dec 14
Chairman recently bought лв338k worth of stock On the 8th of December, Ognian Donev bought around 55k shares on-market at roughly лв6.14 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.2m. New Risk • Dec 08
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 0.9% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (0.9% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Payout ratio: 225% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). Shareholders have been diluted in the past year (31% increase in shares outstanding). Reported Earnings • Dec 01
Third quarter 2023 earnings released: EPS: лв0.12 (vs лв0.20 in 3Q 2022) Third quarter 2023 results: EPS: лв0.12 (down from лв0.20 in 3Q 2022). Revenue: лв465.9m (up 12% from 3Q 2022). Net income: лв14.3m (down 42% from 3Q 2022). Profit margin: 3.1% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Nov 30
Upcoming dividend of лв0.90 per share at 8.4% yield Eligible shareholders must have bought the stock before 07 December 2023. Payment date: 22 January 2024. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 8.4%. Within top quartile of Bulgarian dividend payers (7.4%). Higher than average of industry peers (2.6%). Annonce • Nov 25
Sopharma AD Approves Distribution for the First Half of 2023, Payable on January 22, 2024 Sopharma AD at its EGM held on November 24, 2023, approved the proposal by the Board of Directors for the distribution of 6-month gross dividend amounting to BGN 0.90 (90 stotinki) per share. The persons eligible for dividend are those present in the register of the Central Depository 14 days after the day of the EGM on which the financial statements of the Company for the first half of 2023 was approved and the decision for dividend was taken, namely December 8, 2023 (record date) ex-dividend date December 7, 2023. The starting date for dividend payment is January 22, 2024. New Risk • Nov 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bulgarian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (212% cash payout ratio). Share price has been volatile over the past 3 months (4.8% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв1.6m sold). Annonce • Oct 31
Sopharma AD to Report Q3, 2023 Results on Nov 29, 2023 Sopharma AD announced that they will report Q3, 2023 results on Nov 29, 2023 New Risk • Oct 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (212% cash payout ratio). Shareholders have been diluted in the past year (31% increase in shares outstanding). Significant insider selling over the past 3 months (лв1.6m sold). Recent Insider Transactions • Oct 01
Chairman recently bought лв72k worth of stock On the 28th of September, Ognian Donev bought around 10k shares on-market at roughly лв7.02 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth лв81k. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.5m. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to лв7.18, the stock trades at a trailing P/E ratio of 9.5x. Average forward P/E is 19x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 160% over the past three years. Annonce • Sep 21
Sopharma AD to Report Q3, 2023 Results on Oct 30, 2023 Sopharma AD announced that they will report Q3, 2023 results on Oct 30, 2023 Recent Insider Transactions • Sep 14
Chairman recently bought лв81k worth of stock On the 8th of September, Ognian Donev bought around 13k shares on-market at roughly лв6.20 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.5m. Recent Insider Transactions • Sep 07
Chairman recently sold лв1.1m worth of stock On the 1st of September, Ognian Donev sold around 778k shares on-market at roughly лв1.35 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв1.6m. Annonce • Sep 06
Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia. Sopharma AD (BUL:SFA) acquired a 2.38% stake in Sopharma Buildings REIT-Sofia on September 5, 2023.
Sopharma AD (BUL:SFA) completed the acquisition of a 2.38% stake in Sopharma Buildings REIT-Sofia on September 5, 2023. Reported Earnings • Sep 01
Second quarter 2023 earnings released: EPS: лв0.25 (vs лв0.19 in 2Q 2022) Second quarter 2023 results: EPS: лв0.25 (up from лв0.19 in 2Q 2022). Net income: лв31.2m (up 38% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Aug 31
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (100% cash payout ratio). Shareholders have been diluted in the past year (11% increase in shares outstanding). Significant insider selling over the past 3 months (лв156k sold). Annonce • Jul 16
Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o. Sopharma AD (BUL:SFA) signed an agreement to acquire Pharmanova d.o.o on July 14, 2023. Sopharma will initially acquire an interest of 25% in Pharmanova, then purchase another 50% ownership in a year's time, with the remaining 25% to be bought within two years. The transaction is subject to approval by the Serbian competition authority and is expected to complete within 2 years. As of FY 2022, Pharmanova generated net sales revenue of over €10.2 million. Recent Insider Transactions • Jul 06
Chairman recently sold лв297k worth of stock On the 30th of June, Ognian Donev sold around 28k shares on-market at roughly лв10.57 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ognian has been a net seller over the last 12 months, reducing personal holdings by лв297k. New Risk • Jun 15
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 11% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Upcoming Dividend • Jun 09
Upcoming dividend of лв0.60 per share Eligible shareholders must have bought the stock before 15 June 2023. Payment date: 31 July 2023. The company last paid an ordinary dividend in March 2013. The average dividend yield among industry peers is 2.6%. Annonce • Jun 03
Sopharma AD Declares Dividend for 2022, Payable on 31 July 2023 Sopharma AD announced that, at the General Meeting of Shareholders of the company dated 02 June 2023 has taken the following dividend distribution decision for 2022: Gross dividend per share: BGN 0.60 - Dividend payout starting date: 31 July 2023. Dividend payout: Via the Central Depository and CB Eurobank Bulgaria AD /Postbank/The right to a dividend will be entitled to all shareholders registered with the central securities register on the 14th day following the GMS date, i.e. by 16 June 2023 (Record Date). The final date for transacting shares of this company on the Exchange, so the holder will be entitled to receive a dividend, will be 14 June 2023 (Ex-Dividend Date: 15 June 2023). Reported Earnings • May 31
First quarter 2023 earnings released: EPS: лв0.27 (vs лв0.17 in 1Q 2022) First quarter 2023 results: EPS: лв0.27 (up from лв0.17 in 1Q 2022). Revenue: лв469.9m (up 18% from 1Q 2022). Net income: лв32.3m (up 56% from 1Q 2022). Profit margin: 6.9% (up from 5.2% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 06
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: лв0.60 (down from лв0.71 in FY 2021). Revenue: лв1.67b (up 3.7% from FY 2021). Net income: лв72.6m (down 19% from FY 2021). Profit margin: 4.3% (down from 5.6% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 3 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Dec 22
Sopharma AD, Annual General Meeting, Jun 30, 2023 Sopharma AD, Annual General Meeting, Jun 30, 2023. Major Estimate Revision • Dec 09
Consensus EPS estimates increase by 83% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from лв1.55b to лв1.65b. EPS estimate increased from лв0.29 to лв0.53 per share. Net income forecast to shrink 32% next year vs 13% growth forecast for Pharmaceuticals industry in Europe . Consensus price target up from лв4.17 to лв4.83. Share price was steady at лв4.50 over the past week. Price Target Changed • Dec 08
Price target increased to лв4.83 Up from лв3.98, the current price target is provided by 1 analyst. New target price is 7.3% above last closing price of лв4.50. Stock is up 1.4% over the past year. The company is forecast to post earnings per share of лв0.29 for next year compared to лв0.71 last year. Reported Earnings • Dec 01
Third quarter 2022 earnings released: EPS: лв0.20 (vs лв0.14 in 3Q 2021) Third quarter 2022 results: EPS: лв0.20 (up from лв0.14 in 3Q 2021). Revenue: лв421.0m (flat on 3Q 2021). Net income: лв24.5m (up 34% from 3Q 2021). Profit margin: 5.8% (up from 4.3% in 3Q 2021). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 30
Second quarter 2022 earnings released: EPS: лв0.19 (vs лв0.12 in 2Q 2021) Second quarter 2022 results: EPS: лв0.19 (up from лв0.12 in 2Q 2021). Revenue: лв409.1m (up 7.1% from 2Q 2021). Net income: лв22.7m (up 61% from 2Q 2021). Profit margin: 5.5% (up from 3.7% in 2Q 2021). Over the next year, revenue is expected to shrink by 4.0% compared to a 3.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Annonce • Jun 09
Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million. Sopharma AD (BUL:SFA) made the offer to acquire remaining 66.66% stake in Sopharma Properties REIT (BUL:SFI) for approximately BGN 120 million on June 8, 2022. As per the transaction, Sopharma AD made the offer to acquire remaining 14.6 million shares at BGN 8.2 per share. Reported Earnings • Jun 03
First quarter 2022 earnings released: EPS: лв0.17 (vs лв0.14 in 1Q 2021) First quarter 2022 results: EPS: лв0.17 (up from лв0.14 in 1Q 2021). Revenue: лв399.7m (up 4.8% from 1Q 2021). Net income: лв20.7m (up 14% from 1Q 2021). Profit margin: 5.2% (up from 4.8% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Annonce • May 03
Sopharma AD, Annual General Meeting, Jun 03, 2022 Sopharma AD, Annual General Meeting, Jun 03, 2022. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Alexandar Tchaoushev was the last independent director to join the board, commencing their role in 2011. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Apr 06
Sopharma AD to Report Fiscal Year 2021 Final Results on Apr 29, 2022 Sopharma AD announced that they will report fiscal year 2021 final results on Apr 29, 2022 Reported Earnings • Mar 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: лв0.73 (up from лв0.20 in FY 2020). Revenue: лв1.62b (up 12% from FY 2020). Net income: лв91.4m (up 266% from FY 2020). Profit margin: 5.7% (up from 1.7% in FY 2020). Revenue exceeded analyst estimates by 4.4%. Over the next year, revenue is forecast to stay flat compared to a 7.5% growth forecast for the pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Annonce • Mar 03
Sopharma AD to Report Fiscal Year 2021 Results on Mar 31, 2022 Sopharma AD announced that they will report fiscal year 2021 results on Mar 31, 2022 Annonce • Dec 30
An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA). An unknown buyer has agreed to acquire SIA BRIZ from Sopharma AD (BUL:SFA) on December 29, 2021. Reported Earnings • Dec 02
Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2021 results: EPS: лв0.14. Revenue: лв425.8m (up 24% from 3Q 2020). Net income: лв18.3m (up лв17.1m from 3Q 2020). Profit margin: 4.3% (up from 0.4% in 3Q 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 50%. Earnings per share (EPS) missed analyst estimates by 50%. Over the next year, revenue is forecast to stay flat compared to a 11% growth forecast for the industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year and the company’s share price has also increased by 7% per year. Reported Earnings • Sep 03
Second quarter 2021 earnings released The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: лв384.4m (up 22% from 2Q 2020). Net income: лв14.1m (up 43% from 2Q 2020). Profit margin: 3.7% (up from 3.1% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Sep 03
Chairman recently bought лв79k worth of stock On the 1st of September, Ognian Donev bought around 52k shares on-market at roughly лв1.52 per share. This was the largest purchase by an insider in the last 3 months. This was Ognian's only on-market trade for the last 12 months. Price Target Changed • Jul 26
Price target decreased to лв3.48 Down from лв3.98, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of лв3.48. Stock is up 18% over the past year. Price Target Changed • Jul 19
Price target decreased to лв3.48 Down from лв3.98, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of лв3.44. Stock is up 15% over the past year. Reported Earnings • Jun 02
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: лв382.8m (up 4.1% from 1Q 2020). Net income: лв18.1m (up 68% from 1Q 2020). Profit margin: 4.7% (up from 2.9% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 05
Full year 2020 earnings released: EPS лв0.20 (vs лв0.69 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: лв1.45b (up 12% from FY 2019). Net income: лв25.0m (down 71% from FY 2019). Profit margin: 1.7% (down from 6.8% in FY 2019). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 21
New 90-day high: лв3.50 The company is up 14% from its price of лв3.08 on 20 November 2020. The Bulgarian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Jan 18
New 90-day high: лв3.26 The company is up 5.0% from its price of лв3.10 on 20 October 2020. The Bulgarian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв5.09 per share. Annonce • Jan 10
Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ. Sopharma AD (BUL:3JR) acquired an unknown minority stake in SIA BRIZ on December 28, 2020. As a result of the transaction, Sopharma AD now owns 100% stake in SIA BRIZ.
Sopharma AD (BUL:3JR) completed the acquisition of an unknown minority stake in SIA BRIZ on December 28, 2020. Annonce • Dec 30
An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR). An unknown buyer acquired majority stake of Aromania OOD from Sopharma AD (BUL:3JR) on December 29, 2020.
An unknown buyer completed the acquisition of majority stake of Aromania OOD from Sopharma AD (BUL:3JR) on December 29, 2020. Is New 90 Day High Low • Dec 14
New 90-day high: лв3.18 The company is up 1.0% from its price of лв3.14 on 15 September 2020. The Bulgarian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв5.14 per share. Is New 90 Day High Low • Oct 26
New 90-day high: лв3.16 The company is up 7.0% from its price of лв2.96 on 28 July 2020. The Bulgarian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is лв4.16 per share.